Basel, Switzerland
Basel, Switzerland

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine , diclofenac , carbamazepine , valsartan and imatinib mesylate . Additional agents include cyclosporin , letrozole , methylphenidate , terbinafine , and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations , and the Pharmaceutical Research and Manufacturers of America . Wikipedia.


Time filter

Source Type

Patent
Novartis | Date: 2017-04-12

The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.


Patent
Novartis | Date: 2017-01-20

The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C_(2-20)-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.


Patent
Novartis | Date: 2017-04-12

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.


Method for washing, with a water-based system, reusable molds for making silicone hydrogel contact lenses. The water-based washing system comprises a solvo-surfactant which is an alkyl (propylene glycol)nether wherein alkyl is a linear alkyl group having 2 to 5 carbon atoms and n is the integer 1, 2 or 3. The water-based system of the invention can effectively wash away silicone-containing components and other components of a lens formulation left behind on the molding surfaces of a reusable mold, after removing a silicone hydrogel contact lens cast molded in the reusable mold.


The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.


Patent
Novartis | Date: 2017-03-16

The present invention relates to compounds of formula I: in which n, R_(1), R_(2), R_(3a), R_(4 )and R_(5 )are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.


The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.


Patent
Novartis, Jiang and Xia Llc Inc. | Date: 2017-06-14

This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.


Patent
Novartis | Date: 2017-07-05

An ophthalmic endo-illumination system (206) includes a light source that produces a light beam (305), a fiber port that receives an optical fiber (310), a condenser (302) that couples at least a portion of the light beam into the optical fiber received at the fiber port, and a beam splitter (304) disposed between the fiber port and the condenser. The beam splitter is configured to receive the light beam from the condenser and split the light beam into a first beam (312) which is coupled to the optical fiber and a second beam (314) which is coupled to a monitoring fiber (306). An optical sensor (308) is provided to detect an amount of the second beam output from the monitoring fiber. The coupling efficiency of the first beam coupled into the optical fiber may be determined based on the amount of the second beam output from the monitoring fiber.


Sellers W.R.,Novartis
Cell | Year: 2011

In the era of next-generation sequencing, there are significant challenges to harnessing cancer genome information to develop novel therapies. Key research thrusts in both academia and industry will speed this transition, and lessons learned for cancer will more broadly shape the process for genetic contributions to the therapy of disease more broadly. © 2011 Elsevier Inc.

Loading Novartis collaborators
Loading Novartis collaborators